MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced the presentation of data from MiNK-215, an investigational IL-15 armored fibroblast activation protein (FAP) targeting CAR-iNKT cell therapy, at the American Association for Cancer Research (AACR) Meeting in San Diego, CA.

MiNK Therapeutics，Inc.（纳斯达克：INKT），一家临床阶段的生物制药公司，率先发现，开发和商业化同种异体，现成的不变自然杀伤T（INKT）细胞疗法，以治疗癌症和其他免疫介导的疾病，今天在美国癌症研究协会（AACR）宣布了针对CAR-INKT细胞疗法的IL-15装甲成纤维细胞活化蛋白（FAP）的研究数据在加利福尼亚州圣地亚哥举行会议。

“MiNK-215 represents a novel cellular therapeutic to overcome the limitations of immune checkpoint blockade therapy. The data presented at AACR demonstrate MiNK-215's potential to effectively combat colorectal liver metastases, offering hope for patients who have exhausted conventional treatment options,” said Dr.

“MiNK-215代表了一种新的细胞疗法，可以克服免疫检查点阻断疗法的局限性。AACR上提供的数据表明，MiNK-215具有有效对抗结直肠肝转移的潜力，为已经耗尽常规治疗选择的患者提供了希望，”Dr。

Jennifer Buell, President and Chief Executive Officer at MiNK. “Furthermore, these results accentuate MiNK-215's versatility and synergistic potential when paired with immunotherapies such as Agenus’ botensilimab and balstilimab. This collaboration holds promise in bolstering the anti-tumor response, particularly in the formidable realm of microsatellite stable colorectal cancer.' Liver mets have limited the efficacy of immunotherapy in patients with mismatch repair proficient/microsatellite-stable (pMMR/MSS) colorectal cancer (CRC).

MiNK总裁兼首席执行官詹妮弗·贝尔（JenniferBuell）。“此外，当与Agenus'botensilimab和balstilimab等免疫疗法配对时，这些结果突显了MiNK-215的多功能性和协同潜力。这种合作有望增强抗肿瘤反应，特别是在微卫星稳定的结直肠癌这一令人敬畏的领域。“肝脏mets限制了免疫疗法对错配修复熟练/微卫星稳定（pMMR/MSS）结直肠癌（CRC）患者的疗效。

MiNK's innovative iNKT cell therapy, MiNK-215, has shown the ability to remodel the immunosuppressive tumor microenvironment within the liver. Human organoid models of CRC with liver metastases revea.

MiNK的创新iNKT细胞疗法MiNK-215已显示出重塑肝脏内免疫抑制性肿瘤微环境的能力。具有肝转移的CRC的人类器官模型revea。